{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:28:59Z","timestamp":1792301339239,"version":"4.4.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.lfs.2024.123345","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T17:29:44Z","timestamp":1735493384000},"page":"123345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Progesterone signaling in uterine fibroids: Molecular mechanisms and therapeutic opportunities"],"prefix":"10.1016","volume":"362","author":[{"given":"Ioanna","family":"Ploumaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria I.","family":"Macri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Segars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5595-626X","authenticated-orcid":false,"given":"Md Soriful","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2024.123345_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/aogs.12771","article-title":"Physiology, production and action of progesterone","volume":"94","author":"Taraborrelli","year":"2015","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.lfs.2024.123345_bb0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1210\/er.2012-1043","article-title":"Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer","volume":"34","author":"Kim","year":"2013","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.lfs.2024.123345_bb0015","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.fertnstert.2013.03.007","article-title":"Complex networks of multiple factors in the pathogenesis of uterine leiomyoma","volume":"100","author":"Islam","year":"2013","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0020","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/j.1460-2075.1990.tb08280.x","article-title":"Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B","volume":"9","author":"Kastner","year":"1990","journal-title":"EMBO J."},{"key":"10.1016\/j.lfs.2024.123345_bb0025","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnaa012","article-title":"Selective progesterone receptor modulators\u2014mechanisms and therapeutic utility","volume":"41","author":"Islam","year":"2020","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.lfs.2024.123345_bb0030","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1210\/me.2006-0105","article-title":"Progesterone receptors (PR)-B and-A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B","volume":"20","author":"Tung","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.lfs.2024.123345_bb0035","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.steroids.2008.05.003","article-title":"Heterologous expression of human mPR\u03b1, mPR\u03b2 and mPR\u03b3 in yeast confirms their ability to function as membrane progesterone receptors","volume":"73","author":"Smith","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.lfs.2024.123345_bb0040","article-title":"The role of progesterone receptor membrane component (PGRMC) in the endometrium","volume":"184","author":"Hern\u00e1ndez","year":"2022","journal-title":"Steroids"},{"key":"10.1016\/j.lfs.2024.123345_bb0045","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/mend-4-11-1704","article-title":"Reconstitution of progesterone receptor with heat shock proteins","volume":"4","author":"Smith","year":"1990","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.lfs.2024.123345_bb0050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mce.2011.09.016","article-title":"Progesterone receptors, their isoforms and progesterone regulated transcription","volume":"357","author":"Jacobsen","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.lfs.2024.123345_bb0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrm1009","article-title":"Nongenomic actions of steroid hormones","volume":"4","author":"L\u00f6sel","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.lfs.2024.123345_bb0060","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ygcen.2018.12.002","article-title":"Induction of sperm hypermotility through membrane progestin receptor alpha (mPR\u03b1): a teleost model of rapid, multifaceted, nongenomic progestin signaling","volume":"279","author":"Tan","year":"2019","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.lfs.2024.123345_bb0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.mce.2016.06.027","article-title":"Membrane progesterone receptors in reproduction and cancer","volume":"434","author":"Valadez-Cosmes","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.lfs.2024.123345_bb0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.gene.2016.06.044","article-title":"Progestin-mediated activation of MAPK and AKT in nuclear progesterone receptor negative breast epithelial cells: the role of membrane progesterone receptors","volume":"591","author":"Salazar","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.lfs.2024.123345_bb0075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmet.2006.12.009","article-title":"Dap1\/PGRMC1 binds and regulates cytochrome P450 enzymes","volume":"5","author":"Hughes","year":"2007","journal-title":"Cell Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mce.2008.02.012","article-title":"Expression of progesterone receptor membrane component 1 and its partner serpine 1 mRNA binding protein in uterine and placental tissues of the mouse and human","volume":"287","author":"Zhang","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.lfs.2024.123345_bb0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.repbio.2013.01.170","article-title":"Expression of progesterone receptor membrane component (PGRMC) 1 and 2, serpine mRNA binding protein 1 (SERBP1) and nuclear progesterone receptor (PGR) in the bovine endometrium during the estrous cycle and the first trimester of pregnancy","volume":"13","author":"Kowalik","year":"2013","journal-title":"Reprod. Biol."},{"key":"10.1016\/j.lfs.2024.123345_bb0090","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1210\/en.2013-1991","article-title":"Enhancement of cell surface expression and receptor functions of membrane progestin receptor \u03b1 (mPR\u03b1) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors","volume":"155","author":"Thomas","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2024.123345_bb0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0002-9378(93)90135-6","article-title":"Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas","volume":"169","author":"Brandon","year":"1993","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.lfs.2024.123345_bb0100","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/humrep\/12.4.815","article-title":"Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium","volume":"12","author":"Viville","year":"1997","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.lfs.2024.123345_bb0105","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate\u2606","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0110","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/AOG.0000000000002462","article-title":"Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial","volume":"131","author":"Simon","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.lfs.2024.123345_bb0115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.fertnstert.2024.02.046","article-title":"Functional evidence for two distinct mechanisms of action of progesterone and selective progesterone receptor modulator on uterine leiomyomas","volume":"122","author":"Milewska","year":"2024","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0120","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1210\/en.2009-1225","article-title":"Progesterone is essential for maintenance and growth of uterine leiomyoma","volume":"151","author":"Ishikawa","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2024.123345_bb0125","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1210\/endo-126-2-891","article-title":"Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin\/insulin-like growth factor-I, serum, and estrogen","volume":"126","author":"Katzenellenbogen","year":"1990","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2024.123345_bb0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/humupd\/dmx032","article-title":"Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics","volume":"24","author":"Islam","year":"2018","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.lfs.2024.123345_bb0135","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0015-0282(00)00418-0","article-title":"Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation","volume":"73","author":"Arici","year":"2000","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0140","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.fertnstert.2024.05.004","article-title":"Advances in uterine fibroid research: linking progesterone and the transforming growth factor-\u03b2 signaling pathway","volume":"122","author":"Islam","year":"2024","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0145","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.fertnstert.2018.12.026","article-title":"Ulipristal acetate decreases active TGF-\u03b23 and its canonical signaling in uterine leiomyoma via two novel mechanisms","volume":"111","author":"Lewis","year":"2019","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0150","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.fertnstert.2017.11.023","article-title":"Ulipristal acetate decreases transforming growth factor \u03b23 serum and tumor tissue concentrations in patients with uterine fibroids","volume":"109","author":"Ciebiera","year":"2018","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0155","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/346281a0","article-title":"Negative regulation of transforming growth factor-\u03b2 by the proteoglycan decorin","volume":"346","author":"Yamaguchi","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2024.123345_bb0160","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/humrep\/den025","article-title":"Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer","volume":"23","author":"Morikawa","year":"2008","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.lfs.2024.123345_bb0165","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1210\/en.2013-1763","article-title":"Down-regulation of miR-29b is essential for pathogenesis of uterine leiomyoma","volume":"155","author":"Qiang","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2024.123345_bb0170","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.rbmo.2021.09.005","article-title":"Uterine fibroid vascularization: from morphological evidence to clinical implications","volume":"44","author":"Ciarmela","year":"2022","journal-title":"Reprod. Biomed. Online"},{"key":"10.1016\/j.lfs.2024.123345_bb0175","article-title":"Uterine artery embolization for symptomatic uterine fibroids","volume":"2014","author":"Gupta","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2024.123345_bb0180","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/humupd\/dmt042","article-title":"The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy","volume":"20","author":"Tal","year":"2014","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.lfs.2024.123345_bb0185","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.fertnstert.2020.05.036","article-title":"HMGA2-mediated tumorigenesis through angiogenesis in leiomyoma","volume":"114","author":"Li","year":"2020","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0190","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.fertnstert.2020.07.044","article-title":"HMGA2 involvement in uterine leiomyomas development through angiogenesis activation","volume":"114","author":"Ferrero","year":"2020","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0195","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/28867","article-title":"Role of HIF-1\u03b1 in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis","volume":"394","author":"Carmeliet","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2024.123345_bb0200","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/0008-5472.CAN-07-6339","article-title":"Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia","volume":"68","author":"Mayer","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.123345_bb0205","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/emmm.201302618","article-title":"VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy","volume":"5","author":"Kim","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.lfs.2024.123345_bb0210","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/humrep\/del159","article-title":"Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells","volume":"21","author":"Xu","year":"2006","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.lfs.2024.123345_bb0215","first-page":"2192","article-title":"Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma","volume":"83","author":"Shimomura","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0220","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/humrep\/del035","article-title":"A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells","volume":"21","author":"Wang","year":"2006","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.lfs.2024.123345_bb0225","first-page":"293","article-title":"Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone","volume":"82","author":"Matsuo","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0230","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/PGP.0000000000000158","article-title":"Role of apoptosis in the development of uterine leiomyoma: analysis of expression patterns of bcl-2 and bax in human leiomyoma tissue with clinical correlations","volume":"34","author":"Csatl\u00f3s","year":"2015","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.lfs.2024.123345_bb0235","first-page":"240","article-title":"Regulatory mechanism of Bcl-2 in uterine leiomyomas","volume":"35","author":"Ohara","year":"2008","journal-title":"Clin. Exp. Obstet. Gynecol."},{"key":"10.1016\/j.lfs.2024.123345_bb0240","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1210\/jc.2007-0725","article-title":"Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells","volume":"92","author":"Yin","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0245","first-page":"540","article-title":"Differential regulatory effect of progesterone on the proliferation and apoptosis of uterine leiomyoma tissue explants and primary leiomyoma cell cultures","volume":"25","author":"Voronin","year":"2021","journal-title":"JBRA Assist. Reprod."},{"key":"10.1016\/j.lfs.2024.123345_bb0250","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.fertnstert.2009.11.031","article-title":"The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells","volume":"93","author":"Luo","year":"2010","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0255","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2005-2379","article-title":"A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells","volume":"91","author":"Chen","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0260","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2024.123345_bb0265","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1210\/jc.2008-2093","article-title":"Progestins activate the AKT pathway in leiomyoma cells and promote survival","volume":"94","author":"Hoekstra","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0270","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","article-title":"Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety","volume":"96","author":"Bouchard","year":"2011","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0275","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0301-2115(01)00522-X","article-title":"Mifepristone: bioavailability, pharmacokinetics and use-effectiveness","volume":"101","author":"Sarkar","year":"2002","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.lfs.2024.123345_bb0280","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/jnci\/92.24.1970","article-title":"Effect of mifepristone approval on research remains to be seen","volume":"92","author":"Vastag","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lfs.2024.123345_bb0285","article-title":"Multiple clinical indications of mifepristone: a systematic review","volume":"15","author":"Mathew","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.lfs.2024.123345_bb0290","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.2147\/DDDT.S212157","article-title":"Mifepristone inhibits IGF-1 signaling pathway in the treatment of uterine leiomyomas","author":"Shen","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.lfs.2024.123345_bb0295","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/molehr\/8.12.1071","article-title":"Effects of GnRH analogues, \u2018add-back\u2019 steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression","volume":"8","author":"Chegini","year":"2002","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/j.lfs.2024.123345_bb0300","article-title":"Progesterone receptor antagonist provides palliative effects for uterine leiomyoma through a Bcl-2\/Beclin1-dependent mechanism","volume":"39","author":"Zhang","year":"2019","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.lfs.2024.123345_bb0305","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.fertnstert.2015.12.021","article-title":"Mifepristone inhibits extracellular matrix formation in uterine leiomyoma","volume":"105","author":"Patel","year":"2016","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0310","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10616-021-00455-6","article-title":"The function role and synergic effect of syndecan-1 for mifepristone in uterine leiomyoma","volume":"73","author":"Shen","year":"2021","journal-title":"Cytotechnology"},{"key":"10.1016\/j.lfs.2024.123345_bb0315","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1210\/jc.2009-1286","article-title":"Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells","volume":"94","author":"Luo","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0320","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/0008-5472.CAN-09-2612","article-title":"Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells","volume":"70","author":"Yin","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2024.123345_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080114","article-title":"GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment","volume":"8","author":"Engman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2024.123345_bb0330","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jmig.2005.01.022","article-title":"Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas","volume":"12","author":"Eisinger","year":"2005","journal-title":"J. Minim. Invasive Gynecol."},{"key":"10.1016\/j.lfs.2024.123345_bb0335","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/AOG.0b013e31818aa930","article-title":"Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial","volume":"112","author":"Carbonell Esteve","year":"2008","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.lfs.2024.123345_bb0340","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/IJWH.S28103","article-title":"Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery","volume":"4","author":"Esteve","year":"2012","journal-title":"Int. J. Women\u2019s Health"},{"key":"10.1016\/j.lfs.2024.123345_bb0345","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/IJWH.S42770","article-title":"Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial","volume":"5","author":"Esteve","year":"2013","journal-title":"Int. J. Women\u2019s Health"},{"key":"10.1016\/j.lfs.2024.123345_bb0350","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.fertnstert.2013.10.015","article-title":"Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study","volume":"101","author":"Yerushalmi","year":"2014","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0355","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/jmh.JMH_90_20","article-title":"Mifepristone in fibroids: comparative study of safety and efficacy of biweekly dosage vs daily dosage schedule","volume":"12","author":"Shaikh","year":"2021","journal-title":"J. Mid-life Health"},{"key":"10.1016\/j.lfs.2024.123345_bb0360","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsbmb.2003.12.004","article-title":"In vitro antiprogestational\/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone","volume":"88","author":"Attardi","year":"2004","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.lfs.2024.123345_bb0365","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-017-0812-3","article-title":"Ulipristal acetate: a review in symptomatic uterine fibroids","volume":"77","author":"Garnock-Jones","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2024.123345_bb0370","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.fertnstert.2021.05.079","article-title":"Medical treatment with ulipristal acetate for uterine fibroids: will it be resurrected?","volume":"116","author":"Liu","year":"2021","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0375","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1210\/jc.2004-1569","article-title":"Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly (adenosine 5\u2032-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells","volume":"90","author":"Xu","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0380","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.fertnstert.2019.08.007","article-title":"Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study","volume":"112","author":"Del Bello","year":"2019","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0385","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1177\/1933719114542019","article-title":"Ulipristal acetate modulates the expression and functions of activin A in leiomyoma cells","volume":"21","author":"Ciarmela","year":"2014","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.lfs.2024.123345_bb0390","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/molehr\/gan004","article-title":"Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells","volume":"14","author":"Xu","year":"2008","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/j.lfs.2024.123345_bb0395","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.fertnstert.2015.04.025","article-title":"In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment","volume":"104","author":"Courtoy","year":"2015","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0400","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1210\/jc.2017-02295","article-title":"Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment","volume":"103","author":"Courtoy","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0405","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/1381612826666200121141533","article-title":"The biological impact of ulipristal acetate on cellular networks regulating uterine leiomyoma growth","volume":"26","author":"Tinelli","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.lfs.2024.123345_bb0410","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1933719117728802","article-title":"Ulipristal acetate and extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized placebo controlled trial","volume":"25","author":"Cox","year":"2018","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.lfs.2024.123345_bb0415","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1933719118816836","article-title":"Ulipristal acetate mediates decreased proteoglycan expression through regulation of nuclear factor of activated T-cells (NFAT5)","volume":"26","author":"Britten","year":"2019","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.lfs.2024.123345_bb0420","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.rbmo.2018.04.050","article-title":"Gene expression changes in uterine myomas in response to ulipristal acetate treatment","volume":"37","author":"Courtoy","year":"2018","journal-title":"Reprod. Biomed. Online"},{"key":"10.1016\/j.lfs.2024.123345_bb0425","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1210\/jc.2018-01216","article-title":"A-kinase anchoring protein 13 (AKAP13) augments progesterone signaling in uterine fibroid cells","volume":"104","author":"Ng","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2010.09.059","article-title":"Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study","volume":"95","author":"Nieman","year":"2011","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0435","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.123345_bb0440","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2024.123345_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0450","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejogrb.2016.11.003","article-title":"Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results","volume":"208","author":"Fernandez","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.lfs.2024.123345_bb0455","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/AOG.0000000000002942","article-title":"Ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial","volume":"132","author":"Liu","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.lfs.2024.123345_bb0460","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/aogs.13713","article-title":"Ulipristal acetate vs gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): Short-term results of a double-blind randomized controlled trial","volume":"99","author":"De Milliano","year":"2020","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.lfs.2024.123345_bb0465","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejogrb.2020.06.035","article-title":"Ulipristal acetate versus gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): long term results of a double-blind randomized controlled trial","volume":"252","author":"De Milliano","year":"2020","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.lfs.2024.123345_bb0470","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejogrb.2020.10.058","article-title":"A multi-centre, randomized, non-inferiority trial to compare ulipristal with standard surgical treatment in women with symptomatic uterine fibroids: protocol of the MYOMEX-2 trial","volume":"256","author":"Middelkoop","year":"2021","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.lfs.2024.123345_bb0475","first-page":"130","article-title":"Management of women with uterine fibroids in reproductive center: retrospective analysis of clinical and reproductive outcomes","volume":"74","author":"Miriello","year":"2021","journal-title":"Minerva Obstet. Gynecol."},{"key":"10.1016\/j.lfs.2024.123345_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101995","article-title":"Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding (UCON): a randomised controlled phase III trial","volume":"60","author":"Whitaker","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.lfs.2024.123345_bb0485","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.steroids.2003.09.008","article-title":"Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy","volume":"68","author":"DeManno","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.lfs.2024.123345_bb0490","series-title":"Seminars in Reproductive Medicine","first-page":"58","article-title":"Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11\u03b2-benzaldoxime substituted selective progesterone receptor modulators (SPRMs)","author":"Schubert","year":"2005"},{"key":"10.1016\/j.lfs.2024.123345_bb0495","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1210\/me.2006-0524","article-title":"A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator","volume":"21","author":"Madauss","year":"2007","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.lfs.2024.123345_bb0500","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/humrep\/dez007","article-title":"Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials","volume":"34","author":"Stewart","year":"2019","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.lfs.2024.123345_bb0505","doi-asserted-by":"crossref","DOI":"10.1093\/hropen\/hoz027","article-title":"A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids","volume":"2019","author":"Diamond","year":"2019","journal-title":"Hum. Reprod. Open"},{"key":"10.1016\/j.lfs.2024.123345_bb0510","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1933719107311464","article-title":"Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells","volume":"14","author":"Ohara","year":"2007","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.lfs.2024.123345_bb0515","doi-asserted-by":"crossref","first-page":"E1002","DOI":"10.1152\/ajpendo.00210.2007","article-title":"Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells","volume":"293","author":"Xu","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0520","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1210\/jc.2006-0898","volume":"92","author":"Sasaki","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2024.123345_bb0525","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.fertnstert.2006.11.094","article-title":"A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata","volume":"87","author":"Chwalisz","year":"2007","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0530","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/humrep\/dem026","article-title":"The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata","volume":"22","author":"Williams","year":"2007","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.lfs.2024.123345_bb0535","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/humrep\/det247","article-title":"BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies","volume":"28","author":"Wagenfeld","year":"2013","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.lfs.2024.123345_bb0540","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/humrep\/dew140","article-title":"Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women","volume":"31","author":"Sch\u00fctt","year":"2016","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.lfs.2024.123345_bb0545","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jcph.998","article-title":"Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women","volume":"58","author":"Sch\u00fctt","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123345_bb0550","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.fertnstert.2018.10.012","article-title":"Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study","volume":"111","author":"Bradley","year":"2019","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.lfs.2024.123345_bb0555","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejogrb.2020.05.043","article-title":"Efficacy and safety of vilaprisan in women with uterine fibroids: data from the phase 2b randomized controlled trial ASTEROID 2","volume":"252","author":"Gemzell-Danielsson","year":"2020","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.lfs.2024.123345_bb0560","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.xfss.2023.06.003","article-title":"Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial","volume":"4","author":"Al-Hendy","year":"2023","journal-title":"F&S Sci."},{"key":"10.1016\/j.lfs.2024.123345_bb0565","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","article-title":"Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial","volume":"49","author":"Bagaria","year":"2009","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"10.1016\/j.lfs.2024.123345_bb0570","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/01.AOG.0000243776.23391.7b","article-title":"Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial","volume":"108","author":"Fiscella","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.lfs.2024.123345_bb0575","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/649030","article-title":"Treatment of uterine myoma with 2.5 or 5 mg mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial","volume":"2013","author":"Carbonell","year":"2013","journal-title":"ISRN Obstet. Gynecol."},{"key":"10.1016\/j.lfs.2024.123345_bb0580","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ijgo.12968","article-title":"Effect on surgical decisions: ulipristal acetate as key player in Belgian phase IV registration trial","volume":"147","author":"Verguts","year":"2019","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.lfs.2024.123345_bb0585","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1210\/jc.2008-1104","article-title":"Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy","volume":"93","author":"Wilkens","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524009354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524009354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T21:22:47Z","timestamp":1736976167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524009354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":117,"alternative-id":["S0024320524009354"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123345","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progesterone signaling in uterine fibroids: Molecular mechanisms and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123345"}}